RxDoctor Payments Data

Hope Pittman

Family · Petal, MSNPI 1861087215

Payments from drug & device makers

$3,750in general payments, 2019–2025

Across 187 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$620
  • Bayer$506
  • Johnson & Johnson$442
  • Medtronic$400
  • AbbVie$370
  • Astellas Pharma US Inc$244
  • plus $1K from 31 others

What the payments were for

  • Travel & lodging$1414%
  • Food & beverage$3,37490%
  • Education$2356%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,750 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$55,228
Medicare patients
434
Services billed
1,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron32$23,319
MyrbetriqMirabegron38$17,158
Fesoterodine Fumarate ErFesoterodine Fumarate14$1,636
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav117$1,403
NitrofurantoinNitrofurantoin Macrocrystal59$1,222
Testosterone Cypionate28$1,215
CefuroximeCefuroxime Axetil41$1,143
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst56$712
Tamsulosin Hcl99$655
Finasteride73$628
Oxybutynin Chloride28$418
Oxybutynin Chloride ErOxybutynin Chloride28$285
Ciprofloxacin Hcl49$219
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$209
Levofloxacin25$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$620$23,31932 claims
Astellas Pharma US IncMyrbetriq$244$17,15838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Petal

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →